In the phase II-III ORIENT-32 trial conducted in China, the combination of sintilimab (an anti-programmed death-1 [PD-1] antibody) and bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor [VEGF]) significantly reduced the risk of disease progression and death in patients with unresectable HCC (14). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.